Tirzepatide: The Dual GLP-1/GIP Agonist Guide for Weight Loss

Tirzepatide is the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It activates both GIP and GLP-1 receptors, producing enhanced insulin secretion, reduced glucagon release, and slowed gastric emptying. The addition of GIP receptor agonism is believed to amplify weight loss beyond what GLP-1 alone achieves, potentially through complementary effects on fat metabolism, appetite regulation, and energy expenditure.

Tirzepatide represents a new class of weight-loss medication: the dual incretin agonist. While older drugs like semaglutide target only the GLP-1 receptor, tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is the dominant incretin hormone, responsible for roughly 60-70% of the incretin effect after a meal. Preclinical and clinical data suggest that GIP receptor activation enhances fat oxidation, improves lipid metabolism, and may increase energy expenditure in ways that complement GLP-1's appetite-suppressing effects. This dual mechanism is believed to explain why tirzepatide produced greater weight loss than semaglutide in head-to-head trials. Tirzepatide was developed by Eli Lilly and approved under the brand name Mounjaro for type 2 diabetes in May 2022, followed by Zepbound for weight management in November 2023.

The SURMOUNT clinical trial program established tirzepatide as the most effective injectable weight-loss medication available. In SURMOUNT-1, the largest study, participants without diabetes who received the 15 mg dose lost an average of 22.5% of their body weight over 72 weeks, which is approximately 52 pounds for someone starting at 230 lbs. Over one-third of participants in the high-dose group lost 25% or more of their body weight, a level of weight reduction previously seen only with bariatric surgery. SURMOUNT-2 showed significant efficacy in the harder-to-treat diabetic population, achieving 14.7% weight loss. The SURPASS-2 trial provided direct head-to-head data against semaglutide 1 mg, demonstrating superior weight loss and glycemic control at all tirzepatide doses tested.

Tirzepatide follows a gradual dose-escalation schedule to reduce gastrointestinal side effects. Treatment starts at 2.5 mg weekly for 4 weeks, which is a sub-therapeutic initiation dose. The dose then increases by 2.5 mg every 4 weeks through six possible dose levels: 2.5, 5, 7.5, 10, 12.5, and 15 mg. The maintenance dose can be individualized between 5 mg and 15 mg based on tolerability and clinical response. Patients who cannot tolerate escalation may stay at a lower dose, though higher doses generally produce greater weight loss. Tirzepatide is injected subcutaneously once weekly in the abdomen, thigh, or upper arm, and the injection site should be rotated each week.

Tirzepatide's side effect profile is similar to other incretin-based therapies, with gastrointestinal symptoms being the most common. In the SURMOUNT-1 trial, nausea was reported by 24-33% of participants (depending on dose), but was predominantly mild to moderate in severity and typically resolved during the first 4-8 weeks of each dose step. Discontinuation rates due to adverse events were relatively low at 4.3-7.1% across dose groups in SURMOUNT-1. To minimize side effects, patients should eat slowly, avoid overly large meals, and stay hydrated. Patients should immediately report symptoms of pancreatitis (severe persistent abdominal pain), allergic reactions, or changes in vision.

• Nausea is most common during the first few weeks at each new dose level
• Eating smaller meals and avoiding high-fat foods can reduce GI discomfort
• Adequate hydration is essential to prevent dehydration-related complications
• Dose escalation can be slowed if side effects are bothersome
• Most GI side effects diminish over time with continued treatment

Tirzepatide has a list price of approximately $1,000-$1,200 per month without insurance. Mounjaro is broadly covered by commercial insurance plans for type 2 diabetes, but coverage for Zepbound (weight management indication) is more variable. Eli Lilly has offered manufacturer savings programs that can reduce the cost to $25-$550 per month for eligible commercially insured patients. As with semaglutide, Medicare Part D currently does not cover anti-obesity medications, though policy changes are under consideration. Supply constraints that affected tirzepatide availability through 2024-2025 have improved but may still cause intermittent shortages at specific dose levels.